Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Adagene Inc. (Nasdaq: ADAG) will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The presentation is scheduled for February 17 at 11:20 a.m. ET. Investors can access a webcast of the presentation on Adagene's website for 30 days. Adagene focuses on developing novel antibody-based cancer immunotherapies utilizing its Dynamic Precision Library platform, which includes NEObody™, SAFEbody®, and POWERbody™ technologies.

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11^th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Details on the presentation include:

SVB Leerink 11^th Annual Global Healthcare Conference
Presentation Date: Thursday, February 17^th, 2022
Time: 11:20 a.m. ET

A webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Internal Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

External Contact:
Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What is Adagene's presentation date at the SVB Leerink Conference?

Adagene's presentation at the SVB Leerink 11th Annual Global Healthcare Conference is on February 17, 2022.

What time will Adagene present at the healthcare conference?

Adagene's presentation is scheduled for 11:20 a.m. ET on February 17, 2022.

Where can I watch Adagene's conference presentation?

You can watch Adagene's presentation on their website, where a webcast will be available for 30 days.

What technologies does Adagene use for antibody development?

Adagene utilizes NEObody™, SAFEbody®, and POWERbody™ technologies within its Dynamic Precision Library platform.

What type of company is Adagene?

Adagene is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer immunotherapies.